Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.
Blocks dopamine D2 receptors and also interacts with alpha-adrenergic, serotonergic, histamine H1 and muscarinic receptors, contributing to antipsychotic, sedative and antiemetic effects.
Indications / reported uses
Treatment of psychotic disorders where authorised.
Symptomatic management of severe nausea, vomiting or agitation in selected palliative-care settings, according to local product information.
Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.
PDE/ADE: critical effects, point of departure and justified adjustment factors.
OEL: inhalation hazards, exposure duration and workplace conditions.
OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope
PDE/ADE and OEL/OEB assessment
ReguSight provides project-specific support for Levomepromazine PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Levomepromazine Permitted Daily Exposure (PDE) report (the Levomepromazine PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Levomepromazine Occupational Exposure Limit (OEL) report (the Levomepromazine OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.
Assessment may cover
PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.